Global Aciclovir Market Insights, Forecast to 2028

Aciclovir (ACV), also known as acyclovir, is an antiviral medication. It is primarily used for the treatment of herpes simplex virus infections, chickenpox, and shingles. Other uses include prevention of cytomegalovirus infections following transplant and severe complications of Epstein-Barr virus infection.
Market Analysis and Insights: Global Aciclovir Market
Due to the COVID-19 pandemic, the global Aciclovir market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Generic accounting for % of the Aciclovir global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Aciclovir market size is valued at US$ million in 2021, while the US and Europe Aciclovir are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Aciclovir landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Aciclovir include Greater Pharma, LBS Labs, GlaxoSmithKline, Lex Ano, Salutas, Novartis, Teva, Stada Nordic and Cimed Industria de Medicamentos, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Aciclovir Scope and Segment
Aciclovir market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Aciclovir market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Generic
Patent
Segment by Application
Hospital
Drug Store
By Company
Greater Pharma
LBS Labs
GlaxoSmithKline
Lex Ano
Salutas
Novartis
Teva
Stada Nordic
Cimed Industria de Medicamentos
Reman Drug
L.E.T.I.
Nichi-Iko Pharmaceutical
Choseido Pharmaceutical
Shiono Kemikaru
Towa Yakuhin
Wockhardt
Takata Pharmaceutical
Aliud
Amneal Pharma
Apotex
Arrow
Laboratoires Servier
Sanofi
Mylan
Orion Pharma
Pfizer
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE